Increased thrombin-induced polymerization of fibrinogen associated with high protein carbonyl levels in plasma from patients post myocardial infarction

Free Radical Biology and Medicine

Volumn 48, Issue 2, 2010, Pages 223-229

  Paton, Louise N ^a   Mocatta, Tessa J ^a   Richards, A Mark ^a   Winterbourn, Christine C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiovascular disease; Fibrinogen; Protein carbonyls; Protein oxidation

Indexed keywords

3 CHLOROTYROSINE; 3 NITROTYROSINE; CARBONYL DERIVATIVE; FIBRIN; FIBRINOGEN; POLYMER; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN POLYMERIZATION; THROMBOSIS; TURBIDITY;

EID: 72649093724     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.10.044     Document Type: Article

References (48)

1. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
2. Griendling K.K., and FitzGerald G.A. Oxidative stress and cardiovascular injury: Part II. Animal and human studies. Circulation 108 (2003) 2034-2040
3. Pennathur S., and Heinecke J.W. Oxidative stress and endothelial dysfunction in vascular disease. Curr. Diab. Rep. 7 (2007) 257-264
4. Upston J.M., Niu X., Brown A.J., Mashima R., Wang H., Senthilmohan R., Kettle A.J., Dean R.T., and Stocker R. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am. J. Pathol. 160 (2002) 701-710
5. Brennan M.L., and Hazen S.L. Amino acid and protein oxidation in cardiovascular disease. Amino Acids 25 (2003) 365-374
6. Shishehbor M.H., Aviles R.J., Brennan M.L., Fu X., Goormastic M., Pearce G.L., Gokce N., Keaney Jr. J.F., Penn M.S., Sprecher D.L., Vita J.A., and Hazen S.L. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289 (2003) 1675-1680
7. Zheng L., Nukuna B., Brennan M.L., Sun M., Goormastic M., Settle M., Schmitt D., Fu X., Thomson L., Fox P.L., Ischiropoulos H., Smith J.D., Kinter M., and Hazen S.L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114 (2004) 529-541
8. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., Singh P., Anantharamaiah G.M., Chait A., Brunzell J., Geary R.L., Oram J.F., and Heinecke J.W. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA 101 (2004) 13032-13037
9. Pennathur S., Bergt C., Shao B., Byun J., Kassim S.Y., Singh P., Green P.S., McDonald T.O., Brunzell J., Chait A., Oram J.F., O'Brien K., Geary R.L., and Heinecke J.W. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 279 (2004) 42977-42983
10. Cameron V.A., Mocatta T.J., Pilbrow A.P., Frampton C.M., Troughton R.W., Richards A.M., and Winterbourn C.C. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 47 (2006) 1155-1161
11. Mocatta T.J., Pilbrow A.P., Cameron V.A., Senthilmohan R., Frampton C.M., Richards A.M., and Winterbourn C.C. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol 49 (2007) 1993-2000
12. Pantke U., Volk T., Schmutzler M., Kox W.J., Sitte N., and Grune T. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic. Biol. Med. 27 (1999) 1080-1086
13. Zheng L., Settle M., Brubaker G., Schmitt D., Hazen S.L., Smith J.D., and Kinter M. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem. 280 (2005) 38-47
14. Baldus S., Heeschen C., Meinertz T., Zeiher A.M., Eiserich J.P., Munzel T., Simoons M.L., and Hamm C.W. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
15. Brennan M.L., Penn M.S., Van Lente F., Nambi V., Shishehbor M.H., Aviles R.J., Goormastic M., Pepoy M.L., McErlean E.S., Topol E.J., Nissen S.E., and Hazen S.L. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349 (2003) 1595-1604
16. Nicholls S.J., and Hazen S.L. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1102-1111
17. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., and Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 329 (2003) 23-38
18. Shacter E., Williams J.A., Lim M., and Levine R.L. Differential susceptibility of plasma proteins to oxidative modification: examination by Western blot immunoassay. Free Radic. Biol. Med. 17 (1994) 429-437
19. Pignatelli B., Li C.Q., Boffetta P., Chen Q., Ahrens W., Nyberg F., Mukeria A., Bruske-Hohlfeld I., Fortes C., Constantinescu V., Ischiropoulos H., and Ohshima H. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res. 61 (2001) 778-784
20. Vadseth C., Souza J.M., Thomson L., Seagraves A., Nagaswami C., Scheiner T., Torbet J., Vilaire G., Bennett J.S., Murciano J.C., Muzykantov V., Penn M.S., Hazen S.L., Weisel J.W., and Ischiropoulos H. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J. Biol. Chem. 279 (2004) 8820-8826
21. Lord S.T. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr. Opin. Hematol. 14 (2007) 236-241
22. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., and Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Engl. J. Med. 311 (1984) 501-505
23. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., Haines A.P., Stirling Y., Imeson J.D., and Thompson S.G. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2 (1986) 533-537
24. Rosenberg R.D., and Aird W.C. Vascular-bed-specific hemostasis and hypercoagulable states. N. Engl. J. Med. 340 (1999) 1555-1564
25. Prandoni P., Bilora F., Marchiori A., Bernardi E., Petrobelli F., Lensing A.W., Prins M.H., and Girolami A. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 348 (2003) 1435-1441
26. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 206-211
27. Inada Y., Hessel B., and Blomback B. Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim. Biophys. Acta 532 (1978) 161-170
28. Shacter E., Williams J.A., and Levine R.L. Oxidative modification of fibrinogen inhibits thrombin-catalysed clot formation. Free Radic. Biol. Med. 18 (1995) 815-821
29. Nowak P., Zbikowska H.M., Ponczek M., Kolodziejczyk J., and Wachowicz B. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb. Res. 121 (2007) 163-174
30. Lupidi G., Angeletti M., Eleuteri A.M., Tacconi L., Coletta M., and Fioretti E. Peroxynitrite-mediated oxidation of fibrinogen inhibits clot formation. FEBS Lett. 462 (1999) 236-240
31. Parastatidis I., Thomson L., Burke A., Chernysh I., Nagaswami C., Visser J., Stamer S., Liebler D.C., Koliakos G., Heijnen H.F., Fitzgerald G.A., Weisel J.W., and Ischiropoulos H. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J. Biol. Chem. 283 (2008) 33846-33853
32. Rosenfeld M.A., Leonova V.B., Konstantinova M.L., and Razumovskii S.D. Self-assembly of fibrin monomers and fibrinogen aggregation during ozone oxidation. Biochemistry (Mosc.) 74 (2009) 41-46
33. Richards A.M., Nicholls M.G., Espiner E.A., Lainchbury J.G., Troughton R.W., Elliott J., Frampton C., Turner J., Crozier I.G., and Yandle T.G. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
34. Brennan M.L., Wu W., Fu X., Shen Z., Song W., Frost H., Vadseth C., Narine L., Lenkiewicz E., Borchers M.T., Lusis A.J., Lee J.J., Lee N.A., Abu-Soud H.M., Ischiropoulos H., and Hazen S.L. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 277 (2002) 17415-17427
35. Buss I.H., Senthilmohan R., Darlow B.A., Mogridge N., Kettle A.J., and Winterbourn C.C. 3-Chlorotyrosine as a marker of protein damage by myeloperoxidase in tracheal aspirates from preterm infants: association with adverse respiratory outcome. Pediatr. Res. 53 (2003) 455-462
36. Winterbourn C.C., and Buss I.H. Protein carbonyl measurement by enzyme-linked immunosorbent assay. Methods Enzymol. 300 (1999) 106-111
37. Brennan S.O. Electrospray ionisation analysis of human fibrinogen. Thromb. Haemost. 78 (1997) 1055-1058
38. Carr Jr. M.E., and Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 11 (1978) 46-50
39. Maghzal G.J., Brennan S.O., and George P.M. Fibrinogen B beta polymorphisms do not directly contribute to an altered in vitro clot structure in humans. Thromb. Haemost. 90 (2003) 1021-1028
40. Winterbourn C.C., and Kettle A.J. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic. Biol. Med. 29 (2000) 403-409
41. Winterbourn C.C., Buss I.H., Chan T.P., Plank L.D., Clark M.A., and Windsor J.A. Protein carbonyl measurements show evidence of early oxidative stress in critically ill patients. Crit. Care Med. 28 (2000) 143-149
42. Winterbourn C.C., Bonham M.J., Buss H., Abu-Zidan F.M., and Windsor J.A. Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis. Pancreatology 3 (2003) 375-382
43. Buss I.H., Darlow B.A., and Winterbourn C.C. Elevated protein carbonyls, lipid peroxidation products and myeloperoxidase in tracheal aspirates from premature infants. Pediatr. Res. 47 (2000) 640-645
44. Himmelfarb J., McMonagle E., Freedman S., Klenzak J., McMenamin E., Le P., Pupim L.B., Ikizler T.A., and The P.G. Oxidative stress is increased in critically ill patients with acute renal failure. J. Am. Soc. Nephrol. 15 (2004) 2449-2456
45. Wolberg A.S. Thrombin generation and fibrin clot structure. Blood Rev. 21 (2007) 131-142
46. Weisel J.W., and Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys. J. 63 (1992) 111-128
47. Belisario M.A., Di Domenico C., Pelagalli A., Della Morte R., and Staiano N. Metal-ion catalyzed oxidation affects fibrinogen activity on platelet aggregation and adhesion. Biochimie 79 (1997) 449-455
48. Shishehbor M.H., and Hazen S.L. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr. Atheroscler. Rep. 6 (2004) 243-250